Tirzepatide 10 mg is a dual GIP/GLP-1 receptor agonist research compound supplied for laboratory research only. It is studied in laboratory models of incretin signalling and metabolism.
Dual-Agonist Metabolic Signalling
Tirzepatide is a “twincretin” or dual agonist. Unlike compounds that target a single pathway, it activates both the GLP-1 and GIP receptors. This dual mechanism makes it a subject of interest in research on insulin secretion, glucose handling and metabolic signalling.
Glucose Regulation and Energy Balance
By mimicking these two incretin hormones, tirzepatide is associated with slowed gastric emptying and suppressed glucagon after meals. These mechanisms are examined in studies of glucose regulation, appetite signalling and energy partitioning.
Lipolysis and Adipose Tissue
The GIP component of tirzepatide is believed to play a role in adipocyte function. Research has examined its effects on the sensitivity of fat tissue to metabolic signals and on lipolysis. It is frequently compared with single-agonist compounds in body composition research.
Cardiovascular Research
Tirzepatide is being investigated in cardiovascular and lipid-metabolism research models.
Storage and Purity
This 10 mg vial is synthesised to a high purity profile to support consistency across research protocols. It is supplied lyophilised (freeze-dried) to protect the compound during transit across Australia. Store in a cool, dark place or refrigerate at 2°C to 8°C. Once reconstituted, keep the solution chilled and use it within the recommended laboratory timeframe.
For laboratory and research purposes only. Not for human consumption, medical use, or veterinary use.
